Strong end to VC year as Blend, Naurex and Allakos raise $86m

Venture capital financings for biopharmaceutical companies could end 2012 with a strong showing at the pace that new and early-stage firms are announcing new funding rounds, including at least three deals above $10 million kicking off the last full work week before Christmas and New Year's celebrations.

Venture capital financings for biopharmaceutical companies could end 2012 with a strong showing at the pace that new and early-stage firms are announcing new funding rounds, including at least three deals above $10 million kicking off the last full work week before Christmas and New Year's celebrations.

Oncology-focused Blend Therapeutics in Watertown, Massachusetts and Evanston, Illinois-based Naurex with interests in psychiatry and neurology announced Series B rounds...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category